US EditionFDA taps critic of COVID policies, drug industry to lead vaccines division
- Dr. Vinay Prasad was named on Tuesday by FDA Commissioner Marty Makary to lead the agency's vaccines and biotech drugs program, replacing longtime chief Dr. Peter Marks who resigned in March.
- Prasad gained wider attention during the COVID-19 pandemic after criticizing mask mandates, lockdowns, and expedited vaccine boosters from Pfizer and Moderna, raising questions about his regulatory approach.
- Prasad, a cancer and blood disorders expert at UCSF, has challenged FDA fast-track approvals, showing many cancer drugs lack evidence of improving or extending lives, and has called the FDA ineffective in social media and podcast appearances.
- Prasad criticized his predecessor Marks as merely approving decisions unquestioningly and expressed on Vivek Ramaswamy's podcast last year that Americans might fare better if the FDA were fundamentally restructured or even absent in its present state.
- Prasad’s appointment has sparked concern that vaccine and drug manufacturers could face increased regulatory scrutiny, potentially disrupting the predictability vital to drug development plans that extend over years or decades.
Insights by Ground AI
Does this summary seem wrong?
82 Articles
82 Articles
All
Left
22
Center
42
Right
7
ABC FOX Montana+6 Reposted by 6 other sources
Dr. Vinay Prasad to Head FDA Vaccine, Biologics Division
Key Takeaways
·Missoula, United States
Read Full Article
Trump Administration Installs FDA Critic Vinay Prasad as Head of Vaccine Program
Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, has been named to oversee the agency’s program for vaccines and biotech drugs. FDA Commissioner Dr. Marty Makary announced the appointment Tuesday in a message to agency staff, praising Prasad’s “long and distinguished history in medicine.” Prasad is the latest in a series of medical contrarians and critics of COVID-19 measures to join the f…
Coverage Details
Total News Sources82
Leaning Left22Leaning Right7Center42Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 31%
C 59%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
